Claims for Patent: 9,133,495

Summary for Patent: 9,133,495

Title:	Hybrid suppressor tRNA for vertebrate cells
Abstract:	This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal tRNA\'s, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNA\'s/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in vertebrate cells are also provided. The present invention provides vertebrate cells with translation components, e.g., pairs of orthogonal aminoacyl-tRNA synthetases (O-RSs) and orthogonal tRNA\'s (O-tRNA\'s) and individual components thereof, that are used in vertebrate protein biosynthetic machinery to incorporate an unnatural amino acid in a growing polypeptide chain, in a vertebrate cell.
Inventor(s):	Tian; Feng (San Diego, CA), Norman; Thea (San Diego, CA), Chu; Stephanie (San Diego, CA)
Assignee:	Ambrx, Inc. (La Jolla, CA)
Application Number:	12/440,015
Patent Claims:	1. An isolated vertebrate cell or cell line comprising a polynucleotide comprising the nucleotide sequence as set forth in SEQ ID NO: 88, wherein said nucleotide sequence encodes an orthogonal tRNA. 2. The cell or cell line of claim 1, wherein the nucleotide sequence encodes a tNRA molecule that has an anticodon recognition sequence that is specific for a selector codon. 3. The cell or cell line of claim 2, wherein the selector codon is selected from the group consisting of: amber codon, ochre codon, opal codon, or four or more base codons. 4. The cell or cell line of claim 2, wherein the nucleotide sequence encodes tRNA molecule that is capable of being aminoacylated with at least one non-natural amino acid. 5. The cell or cell line of claim 1, wherein the orthogonal tRNA is capable of aminoacylation with a natural amino acid or a non-natural amino acid. 6. The cell or cell line of claim 1, wherein the orthogonal tRNA is capable of aminoacylation with a natural amino acid and a non-natural amino acid. 7. The cell or cell line of claim 1, wherein the orthogonal tRNA is capable of aminoacylation with a non-natural amino acid. 8. The cell or cell line of claim 1, wherein the vertebrate cell or cell line is a mammalian cell or cell line. 9. The cell or cell line of claim 8, wherein the vertebrate cell or cell line is CHO-K1. 10. The cell or cell line of claim 8, wherein the vertebrate cell or cell line is CHO DG-44. 11. The cell or cell line of claim 8, wherein the vertebrate cell or cell line is a human cell or cell line. 12. The cell or cell line of claim 7, wherein the non-natural amino acid is selected from the group consisting of: a p-acetyl-L-phenylalanine, a p-iodo-L-phenylalanine, an O-methyl-L-tyrosine, a p-propargyloxyphenylalanine, an L-3-(2-naphthyl)alanine, a 3-methyl-phenylalanine, an O-4-allyl-L-tyrosine, a 4-propyl-L-tyrosine, a tri-O-acetyl-GlcNAcl3-serine, an L-Dopa, a fluorinated phenylalanine, an isopropyl-L-phenylalanine, a p-azido-L-phenylalanine, a p-acyl-L-phenylalanine, a p-benzoyl-L-phenylalanine, an L-phosphoserine, a phosphonoserine, a phosphonotyrosine, a p-bromophenylalanine, a p-amino-L-phenylalanine, an isopropyl-L-phenylalanine, an unnatural analogue of a tyrosine amino acid; an unnatural analogue of a glutamine amino acid; an unnatural analogue of a phenylalanine amino acid; an unnatural analogue of a serine amino acid; an unnatural analogue of a threonine amino acid; art alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkynl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine, keto, or amino substituted amino acid, or any combination thereof; an amino acid with a photoactivatable cross-linker; a spin-labeled amino acid; a fluorescent amino acid; a metal binding amino acid; a metal-containing amino acid; a radioactive amino acid; a photocaged and/or photoisomerizable amino acid; a biotin or biotin-analogue containing amino acid; a keto containing amino acid; an amino acid comprising polyethylene glycol or polyether; a heavy atom substituted amino acid; a chemically cleavable or photocleavable amino acid; an amino acid with an elongated side chain; an amino acid containing a toxic group; a sugar substituted amino acid; a carbon-linked sugar-containing amino acid; a redox-active amino acid; an .alpha.-hydroxy containing acid; an amino thio acid; an .alpha.,.alpha. disubstituted amino acid; a .beta.-amino acid; a cyclic amino acid other than proline or histidine, and an aromatic amino acid other than phenylalanine, tyrosine or tryptophan. 13. The cell or cell line of claim 8, further comprising an orthogonal tRNA synthetase (O-RS), wherein the O-RS recognizes the tRNA, and the tRNA is preferentially aminoacylated with a non-natural amino acid by the O-RS. 14. The cell or cell line of claim 13, wherein the O-RS is obtained from a non-vertebrate organism. 15. The cell or cell line of claim 13, wherein the O-RS is encoded by the nucleotide sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 86, or conservative variants thereof. 16. The cell or cell line of claim 14, wherein the non-vertebrate organism is Escherichia coli, or Bacillus stearothermophilus. 17. The cell or cell line of claim 13, further comprising a nucleic acid that comprises a polynucleotide that encodes a polypeptide of interest, wherein the polynucleotide comprises a selector codon that is recognized by the O-tRNA. 18. The cell or cell line of claim 17, wherein the polypeptide of interest is a therapeutic protein, a diagnostic protein, an industrial enzyme, or portion thereof. 19. The cell or cell line of claim 17, wherein the polypeptide of interest comprises a protein or a portion of a protein selected from the group consisting of: a cytokine, a growth factor, a growth factor receptor, an interferon, an interleukin, an inflammatory molecule, an oncogene product, a peptide hormone, a signal transduction molecule, a steroid hormone receptor, erythropoietin (EPO), insulin, human growth hormone, an Alpha-1 antitrypsin, an Angiostatin, an Antihemolytic factor, an antibody, an Apolipoproteirt, an Apoprotein, an Atrial natriuretic factor, an Atrial natriuretic polypeptide, an Atrial peptide, a C-X-C chemokine, NAP-2, ENA-78, a Gro-a, a Gro-b, a Gro-c, an IP-10, a GCP-2, an NAP-4, an SDF-1, a PF4, a MIG, a Calcitonin, a c-kit ligand, a CC chemokine, a Monocyte chemoattractant protein-I, a Monocyte chemoattractant protein-2, a Monocyte chemoattractant protein-3, a Monocyte inflammatory protein-1 alpha, a Monocyte inflammatory protein-1 beta, RANTES, a CD40, a CD40 ligand, a C-kit Ligand, a Collagen, a Colony stimulating factor (CSF), a Complement factor 5a, a Complement inhibitor, a Complement receptor 1, DHFR, an epithelial Neutrophil Activating Peptide-78, a GRO.alpha./MGSA, a GRO.beta., a GRO.gamma. a MIP-1.alpha., a MIP-1.delta., a MCP-1, an Epidermal Growth Factor (EGF), an epithelial Neutrophil Activating Peptide, an Exfoliating toxin, a Factor IX, a Factor VII, a Factor VIII, a Factor X, a Fibroblast Growth Factor (FGF), a Fibrinogen, a Fibronectin, a G-CSF, a GM-CSF, a Glucocerebrosidase, a Gonadotropin, a Hedgehog protein, a Hemoglobin, a Hepatocyte Growth Factor (HGF), a Hirudin, a Human serum albumin, an ICAM-1, an ICAM-1 receptor, an LFA-1, an LFA-1 receptor, an Insulin-like Growth Factor (IGF), an IGF-I, an IGF-II, an IFN-.alpha., an IFN-.beta., an IFN-.gamma., an IL-1, an IL-2, an IL-3, an IL-4, an IL-5, an IL-6, an IL-7, an IL-8, an IL-9, an IL-10, an IL-11, an IL-12, a Keratinocyte Growth Factor (KGF), a Lactoferrin, a leukemia inhibitory factor, a Luciferase, a Neurmrin, a Neutrophil inhibitory factor (NIF), an oncostatin M, an Osteogenic protein, a Parathyroid hormone, a PD-ECSF, a PDGF, a Pleiotropin, a Protein A, a Protein G, a Pyrogenic exotoxins A, B, or C, a Relaxin, a Renin, an SCF, a Soluble complement receptor I, a Soluble I-CAM 1, a Soluble interleukin receptor, a Soluble TNF receptor, a Somatomedin, a Somatostatin, a Somatotropin, a Streptokinase, a Superantigen, a Staphylococcal enterotoxins, an SEA, an SEB, an SEC1, an SEC2, an SEC3, an SED, an SEE, a Superoxide dismutase (SOD), a Toxic shock syndrome toxin, a Thymosin alpha 1, a Tissue plasminogen activator, a tumor growth factor (TGF), a TGF-.alpha., a TGF-.beta., a Tumor Necrosis Factor, a Tumor Necrosis Factor alpha, a Tumor necrosis factor beta, a Tumor necrosis factor receptor (TNFR), a VLA-4 protein, a VCAM-1 protein, a Vascular Endothelial Growth Factor (VEGEF), a Urokinase, a Mos, a Ras, a Raf, a Met; a p53, a Tat, a Fos, a Myc, a Jun, a Myb, a Rel, an estrogen receptor, a progesterone receptor, a testosterone receptor, an aldosterone receptor, an LDL receptor, a SCF/c-Kit, a CD40L/CD40, a VLA-4/VCAM-1, an ICAM-1/LFA-1, a hyalurin/CD44, and a corticosterone. 20. An isolated A vertebrate cell comprising an orthogonal tRNA encoded by SEQ ID NO: 88, an orthogonal aminoacyl tRNA synthetase (O-RS), a non-natural amino acid, and a nucleic acid that comprises a polynucleotide that encodes a polypeptide of interest, wherein the polynucleotide comprises a selector codon that is recognized by the tRNA, wherein the O-RS preferentially aminoacylates the tRNA with the non-natural amino acid in the vertebrate cell, and wherein the cell produces the polypeptide of interest in the presence of the non-natural amino acid. 21. The cell or cell line of claim 1, wherein the nucleotide sequence comprises an A box and a B box. 22. The cell or cell line of claim 1, wherein the cell or cell line has been stably transfected with the polynucleotide. 23. The cell or cell line of claim 1, wherein the cell or cell line has been transiently transfected with the polynucleotide. 24. A kit for producing a protein that comprises at least one unnatural amino acid, the kit comprising: a container containing an orthogonal tRNA encoded by the polynucleotide sequence set forth in SEQ ID NO:88 and wherein the orthogonal tRNA mediates the incorporation of the unnatural amino acid into an expressed protein. 25. The kit of claim 24, wherein the kit further comprises at least one unnatural amino acid. 26. The kit of claim 24, wherein the kit further comprises instructional materials for producing the protein.

Details for Patent 9,133,495

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2026-09-08
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2026-09-08
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2026-09-08
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2026-09-08
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	05/25/2018		2026-09-08